The associations between KCNQ1 polymorphisms and increased risk for GDM not only indicate similar pathogenic mechanisms with T2DM but also make KCNQ1 a novel potential therapeutic target for both T2DM and GDM. Here, KCNQ1 is linked to type 2 diabetes mellitus.